Symbiotec Pharmalab Ltd. IPO opens for subscription on Aug. 24 and will remain open until Aug. 27. The Rs 1,757 crore public issue comprises a fresh issue and an offer-for-sale (OFS).
The IPO comes amid strong grey market interest, with Symbiotec Pharmalab shares commanding a premium of more than 37% ahead of the issue opening.
Symbiotec Pharmalab IPO GMP Today
As of 8:30 a.m. on Aug. 24, the grey market premium (GMP) for the Symbiotec Pharmalab IPO stood at Rs 409 per share. With the IPO's upper price band fixed at Rs 988, the estimated listing price based on the prevailing GMP is Rs 1,397.
If the current grey market trend holds, Symbiotec Pharmalab shares could list at a premium of around 41.40% over the IPO upper price band.
Note: GMP does not represent official data and is based on speculation. The actual listing price may differ.
ALSO READ: Atomberg IPO: Jungle Ventures-Backed Company Files DRHP For Rs 450 Crore Fresh Issue
Symbiotec Pharmalab IPO Details
The Symbiotec Pharmalab IPO is a book-built issue worth Rs 1,757 crore. The public issue consists of a fresh issue of shares and an offer-for-sale by existing shareholders.
- Fresh issue: 15 lakh shares aggregating to Rs 150 crore
- Offer-for-sale (OFS): 1.63 crore shares aggregating to Rs 1,607 crore
- IPO price band: Rs 938 to Rs 988 per share
- Lot size: 15 shares
- Minimum retail investment: Rs 14,820 at the upper price band
- Issue size: Rs 1,757 crore
JM Financial Ltd. is the book running lead manager for the issue, while MUFG Intime India Pvt. Ltd. is the registrar.
Symbiotec Pharmalab IPO Allotment and Listing
The Symbiotec Pharmalab IPO allotment is expected to be finalised on Aug. 28. Investors can check their allotment status after the finalisation of the basis of allotment.
Symbiotec Pharmalab shares are scheduled to be listed on both the NSE and BSE. The tentative listing date is Sept. 1.
Symbiotec Pharmalab Financials
Symbiotec Pharmalab reported growth in both revenue and profit in FY26. Total income rose 15% to Rs 872.26 crore in FY26 from Rs 755.98 crore in FY25, while profit after tax (PAT) increased 14% to Rs 109.9 crore from Rs 96.79 crore.
| Period Ended | FY26 | FY25 |
| Total Income | Rs 872.26 crore | Rs 755.98 crore |
| Profit After Tax | Rs 109.9 crore | Rs 96.79 crore |
| EBITDA | Rs 231.97 crore | Rs 206.11 crore |
Symbiotec Pharmalab IPO Proceeds
The company plans to use the proceeds from the fresh issue for:
- Prepayment and/or repayment of outstanding borrowings
- General corporate purposes
Since a substantial portion of the IPO comprises an OFS, the proceeds from those shares will accrue to the selling shareholders rather than the company.
Symbiotec Pharmalab Business
Incorporated in 2002, Symbiotec Pharmalab Ltd. operates in the pharmaceutical and biotechnology sector. The company manufactures APIs, nutritional ingredients and speciality products for global markets.
Its operations are supported by a backward-integrated manufacturing platform, which enables the company to manage several stages of the production process. Symbiotec Pharmalab has more than three decades of industry experience and caters to customers across international markets.
Disclaimer: Investments in initial public offerings are subject to market risks. Please consult with financial advisors and read the red herring prospectus thoroughly before placing bids.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.